Regulatory reforms that improve the competitive landscape for biosimilars will promote drug affordability while incentivizing ...
Pharmacy benefit managers take considerably different approaches to managing patient access to biosimilars, or cheaper ...
Merck’s Keytruda holds on to the top spot while AbbVie’s Humira—once the world’s top-selling drug—continues to cede its ...
Omlyclo is used for the treatment of moderate to severe persistent asthma, chronic rhinosinusitis with nasal polyps, ...
The FDA has approved two new biosimilars of denosumab for all indications of the reference medications Prolia and Xgeva, ...
The US shift toward steep tariffs will likely make drugs more expensive and limit access for patients, according to one of ...
OMLYCLO® (omalizumab-igec) is the first and only omalizumab biosimilar approved by the FDA Regulatory approval for ...
Ad hoc announcement pursuant to art. 53 SIX Swiss Exchange Listing RulesMEDIA RELEASEFY 2024 net sales[1] of USD 10.4 billion, up by 9%[2] in ...
FYB202/Otulfi ® (ustekinumab-aauz), a biosimilar to Stelara®, launched in the United States and the European Union FYB202/Otulfi ® is now commercially available in both subcutaneous and intravenous ...
Regeneron recently announced it would initiate a quarterly dividend of $0.88, a competitive amount for a company first ...
Celltrion today announced the U.S. launch of STEQEYMA��(ustekinumab-stba), a biosimilar to STELARA� (ustekinumab), following approval by the U.S. Food and Drug Administration (FDA) in December 2024.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results